• Dosage of Cetoconazol Aurovitas in details
• Cetoconazol Aurovitas interactions
• Cetoconazol Aurovitas reviews

Dosage of Cetoconazol Aurovitas in details

Cetoconazol Aurovitas Dosage

Generic name: Cetoconazol Aurovitas 200mg

Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

There should be laboratory as well as clinical documentation of infection prior to starting Cetoconazol Aurovitas therapy. The usual duration of therapy for systemic infection is 6 months. Treatment should be continued until active fungal infection has subsided.

Adults

The recommended starting dose of Cetoconazol Aurovitas® (Cetoconazol Aurovitas) Tablets is a single daily administration of 200 mg (one tablet). If clinical responsiveness is insufficient within the expected time, the dose of Cetoconazol Aurovitas® Tablets may be increased to 400 mg (two tablets) once daily.

Children

In small numbers of children over 2 years of age, a single daily dose of 3.3 to 6.6 mg/kg has been used. Cetoconazol Aurovitas® Tablets have not been studied in children under 2 years of age.

More about Cetoconazol Aurovitas (Cetoconazol Aurovitas)

• Side Effects
• During Pregnancy or Breastfeeding
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• En Espanol
• 4 Reviews - Add your own review/rating

Consumer resources

• Cetoconazol Aurovitas
• Cetoconazol Aurovitas (Advanced Reading)

Professional resources

• Cetoconazol Aurovitas (AHFS Monograph)
• Cetoconazol Aurovitas (FDA)

Other formulations

• Cetoconazol Aurovitas

  Topical

• Cetoconazol Aurovitas A-D

Related treatment guides

• Blastomycosis
• Chromomycosis
• Coccidioidomycosis
• Histoplasmosis
• Paracoccidioidomycosis

What other drugs will affect Cetoconazol Aurovitas?

Many drugs can interact with Cetoconazol Aurovitas. Below is just a partial list. Tell your doctor if you are using:

• acetaminophen (Tylenol);
• cyclosporine (Gengraf, Sandimmune, Neoral);
• clopidogrel (Plavix);
• digoxin (digitalis, Lanoxin);
• tacrolimus ((Prograf);
• loratadine (Alavert, Claritin, Tavist ND);
• methylprednisolone (Medrol);
• phenytoin (Dilantin);
• rifampin (Rifadin, Rifater, Rifamate, Rimactane);
• diabetes medication you take by mouth;
• a sedative such as midazolam (Versed);
• a blood thinner such as warfarin (Coumadin);
• cancer medications;
• birth control pills or hormone replacement therapy;
• methotrexate (Rheumatrex, Trexall);
• cholesterol medications such as niacin (Advicor), atorvastatin (Lipitor), lovastatin (Altocor, Mevacor), simvastatin (Zocor), and others; or
• medications to treat HIV or AIDS.

This list is not complete and there are many other drugs that can interact with Cetoconazol Aurovitas. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Cetoconazol Aurovitas interactions

Drugs that affect the absorption, distribution, metabolism, and excretion of Cetoconazol Aurovitas may alter the plasma concentrations of Cetoconazol Aurovitas. For example, gastric acid suppressants (e.g., antacids, histamine H2-blockers, proton pump inhibitors) have been shown to reduce plasma concentrations of Cetoconazol Aurovitas.

Cetoconazol Aurovitas is a substrate and potent inhibitor of CYP3A4. Therefore, the following drug interactions may occur when Cetoconazol Aurovitas® is co-administered with other drugs that interact with CYP3A4.

1. Cetoconazol Aurovitas® may decrease the elimination of drugs metabolized by CYP3A4, thereby increasing their plasma concentrations. Increased exposure to these drugs may cause an increase or prolongation of their therapeutic and/or adverse effects. Concomitant use with Cetoconazol Aurovitas® Tablets is contraindicated for drugs known to present a risk of serious side effects with increased exposure. For others, monitoring of plasma concentrations is advised when possible. Clinical signs and symptoms associated with these drugs should be monitored, with dosage adjusted as needed.
2. Inducers of CYP3A4 may decrease the plasma concentrations of Cetoconazol Aurovitas. Cetoconazol Aurovitas® may not be effective in patients concomitantly taking one of these drugs. Therefore, administration of these drugs with Cetoconazol Aurovitas® is not recommended.
3. Other inhibitors of CYP3A4 may increase the plasma concentrations of Cetoconazol Aurovitas. Patients who must take Cetoconazol Aurovitas® concomitantly with one of these drugs should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effects of Cetoconazol Aurovitas®.

Table 1: Selected Drugs That Have Been Shown To or Are Predicted To Have Their Plasma Concentrations Altered By Cetoconazol Aurovitas®*

Table 2: Selected Drugs That Have Been Shown To or Are Predicted To Alter The Plasma Concentration Of Cetoconazol Aurovitas®

Effects of Cetoconazol Aurovitas on other drugs

Systemic exposure to the following drugs is significantly increased by co